Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy is organized by Physicians' Education Resource, LLC (PER).
Release Date: January 31, 2023
Expiration Date: January 31, 2024.
Description:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematological malignancy that is derived from the precursors of plasmacytoid dendritic cells. A greater understanding of BPDCN’s unique clinical presentation, clinical course, and disease biology led to reclassification of this disease as a myeloid neoplasm. Early recognition of BPDCN has been challenging because its clinical features can be heterogeneous and can overlap other hematologic malignancies. Outcomes for patients with BPDCN are historically poor, but improved knowledge of disease pathology has led to increased targeted treatment options and standardization.
This Community Practice Connection™ provides an in-depth review of some of the key highlights from a live symposium held at the 64th American Society of Hematology Annual Meeting in December 2022. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with hematologic malignancies, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Explain the clinical presentation, cytogenetics, and pathophysiological mechanisms of BPDCN
• Apply criteria for the timely diagnosis of BPDCN, including methods for differential diagnosis, through optimization of multidisciplinary collaboration
• Assess the clinical profiles of current and emerging CD123-targeted therapeutic approaches that have been investigated for the treatment of patients with BPDCN
• Incorporate updated guidelines and pivotal trial data on current/emerging agents targeting CD123 into personalized treatment plans for patients with BPDCN.
Additional details will be posted as soon as information is available.